History
2020s
·2020 Anhui Yongshengtang Pharmaceutical was acquired and Gansu Lanzhou Chemical Technology was established, further expanding our business footprint.
·2023 Taizhou Iodine Source Technology was founded to restructure and optimize our iodine-based portfolio. Following the associated shareholding system reform, the company was officially renamed Zhejiang Haizhou Pharmaceutical Co., Ltd.
·2024 Zhejiang Shengze New Materials was acquired to complement and broaden our business portfolio.
2010s
·2010 Three new workshops for the production of contrast media intermediates were built.
·2011 Maiden clearance from the U.S. FDA was achieved, with a RMB15 million capital injection being approved to upgrade wastewater- and off-gas-treatment systems.
·2012 The improved waste treatment facility was commissioned.
·2014 The company's name was shortened to Zhejiang Haizhou Pharmaceutical Co., Ltd.
·2015 Our first EHS audit by a Fortune 500 pharmaceutical company was undertaken and successfully passed.
·2017 Ningbo Harvest Polymer Technology Co., Ltd. was acquired to broaden the scope of our business.
·2019 Our Contrast Media API production facilities secured cGMP certification.
2000s
·2003 To meet with the requirements for environmental protection and cater for future expansion, Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd. relocated to the Yanhai Industrial Park, a national-level API production base.
·2004 Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd was acquired by the current shareholders, converting the business from a state-owned enterprise to a private entity. As part of the process, cGMP inspection was passed and the GMP certificate for guaifenesin was awarded.
·2005 The production of contrast media intermediates was initiated by Zhejiang Jianfeng Haizhou Pharmaceutical Co.
·2006 Infrastructure at the Yanhai Industrial Park was extended, with the addition of two multifunctional workshops to improve CMO services.
·2008 ISO 9001, ISO 14001 and OHSAS 18001 certifications were awarded.
·2009 Zhejiang Jianfeng Haizhou Pharmaceutical Co was designated as a National High-Tech Enterprise; EDQM-approved Guaifenesin API facilities were audited by Wyeth, Johnson & Johnson and Sanofi.
1990s
·1996 Production of the expectorant guaifenesin was initiated.
·1997 The company was renamed as Zhejiang Jianfeng Haizhou Pharmaceutical Co., Ltd.
YOUR EMAIL
If you are interested in our products, please leave your email.
CONTACT
Copyright © 2025 Zhejiang Haizhou Pharmaceutical Co., Ltd. 丨 SEO
Business License